• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

The Oversimplification of Cholesterol Testing Can Be Deadly
Early every year, countless Americans embark on a new fitness regime. They go for a physical and maybe for a blood test to measure cholesterol levels. After a clean bill of health, they might train to run a 10K, a marathon or even an Iron man. But what if those tests do not provide a complete picture of your health? What if you are on the verge of a heart attack and have no idea? Before 30, when the human body is at its peak, it can take the strain of being pushed to the limit. As we age, however, cellular changes and the expression of genetic predispositions can dramatically alter our health. Conventional medical tests a...
Source: Healthy Living - The Huffington Post - April 6, 2016 Category: Consumer Health News Source Type: news

Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation.
Conclusions:In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events. PMID: 25739954 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 24, 2015 Category: Cardiology Authors: Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, Ogawa H, on behalf of the Kumamoto Inter Tags: Circ J Source Type: research

Statins for primary prevention of venous thromboembolism.
CONCLUSIONS: Available evidence showed that rosuvastatin was associated with a reduced incidence of VTE, but the evidence was limited to a single RCT and any firm conclusions and suggestions could be not drawn. Randomised controlled trials of statins (including rosuvastatin) are needed to evaluate their efficacy in the prevention of VTE. PMID: 25518837 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 18, 2014 Category: Journals (General) Authors: Li L, Zhang P, Tian JH, Yang K Tags: Cochrane Database Syst Rev Source Type: research